Ophthalmology Times
We’ve noticed that you’re using an ad blockerOur content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
We’ve noticed that you’re using an ad blockerOur content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
At this year’s ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic…
Priorities can ensure optimal outcomes for patients diagnosed with diseases.
The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of…
Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.
More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.
The A-IOL aims to correct both near and distance eyesight, reduce reliance on glasses or contact lenses, have no glare or halos, and restore the…
The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of…
The data will be presented in oral session at the 2024 American Society of Gene & Cell Therapy meeting May 7-11 in Baltimore, Maryland.
David Hutton, Managing Editor of Ophthalmology Times sat down with Claris Bio CEO, Clarke Atwell, to discuss the company’s path toward developing treatment for neurotrophic…
Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.